XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Long-Term Investments (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
Mar. 14, 2024
Long-Term Investments [Line Items]        
Percentage of common stock shares 51.00%      
Aggregate amount     $ 2,688,578  
Prepayment amount     $ 1,895,556  
Converted shares     994,450  
Common stock, shares authorized [1] 100,000,000 100,000,000    
Ordinary shares issued 12,051,823 [1] 7,940,298 [1]   1,610,700
Ordinary shares outstanding [1] 12,051,823 7,940,298    
Joint venture $ 150,000      
BioFirst Corporation [Member]        
Long-Term Investments [Line Items]        
Percentage of common stock shares 18.68% 18.68%    
Prepayment amount $ 1,124,842      
Ordinary shares issued 3,049      
Ordinary shares outstanding 3,049      
Rgene Corporation [Member]        
Long-Term Investments [Line Items]        
Percentage of common stock shares 26.65% 26.65%    
BioLite Japan K.K. [Member]        
Long-Term Investments [Line Items]        
Percentage of common stock shares 49.00%      
Common stock, shares authorized 10,000      
Ordinary shares issued 1,555      
Joint venture $ 150,000      
BioLite JP [Member]        
Long-Term Investments [Line Items]        
Ordinary shares issued 1,494      
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.